windlas biotech has announced a buyback offer to purchase up to 4,70,000 fully paid-up equity shares, representing 2.23% of the total equity shares in the existing total paid-up equity share capital of the company. The buyback will be conducted on a proportionate basis through the tender offer route under the Securities and Exchange Board of India (Buyback of Securities) Regulations 2018.

The buyback price has been fixed at INR 1,000 per equity share, payable in cash, for an aggregate maximum amount not exceeding INR 47,00,00,000, excluding transaction costs. The equity shares have a face value of INR 5 each. The offer is open to all eligible shareholders as on the record date of Friday, April 24, 2026.

Buyback Schedule and Key Dates

The buyback window is scheduled to open on April 30, 2026 and close on May 07, 2026. The last date for receipt of completed tender forms and other specified documents by the registrar is May 07, 2026 by 5 PM IST. Tendering of shares will not be permitted on May 01, 2026 due to a SEBI holiday.

Buyback Entitlement Details

The buyback entitlement ratio is the same for both categories of eligible shareholders. The actual buyback entitlement factor is 0.058451336 for both small shareholders under the reserved category and other shareholders under the general category.

Process and Documentation

The Letter of Offer was submitted to SEBI on April 27, 2026 and dispatched to eligible shareholders on the same date through electronic mode and on April 28, 2026 through speed post. The Letter of Offer and Tender Forms are available on the company website at www.windlas.com , the registrar's website at www.in.mpsm.mufg.com , the manager's website at www.fintellectualadvisors.com , SEBI website at www.sebi.gov.in , BSE at www.bseindia.com and NSE at www.nseindia.com .

For the purpose of this buyback, BSE is the designated stock exchange. Eligible shareholders may place orders in the acquisition window through their respective stockbrokers during normal trading hours. In case shareholders have not received the Letter of Offer, they can download it from the websites mentioned above. Fintellectual Corporate Advisors Private Limited is the manager to the buyback, while MUFG Intime India Private Limited serves as the registrar to the buyback.

Windlas Biotech Limited's Board of Directors has approved a significant share buyback program worth ₹47 crore, demonstrating the company's commitment to returning value to shareholders. The decision was made during a board meeting held on April 17, 2026, with the record date set for April 24, 2026.

Buyback Program Details

The board approved the buyback of up to 4,70,000 fully paid-up equity shares, each with a face value of ₹5.00. The buyback will be conducted at ₹1,000 per equity share, payable in cash, for a total amount not exceeding ₹47 crore.

Regulatory Compliance and Structure

The buyback represents 9.80% of the aggregate total paid-up equity share capital and free reserves based on the company's latest audited standalone and consolidated financial statements as of March 31, 2025. The program will be conducted through the tender offer route as prescribed under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018.

Notably, promoters and members of the promoter group have indicated their intention not to participate in the proposed buyback. The company will reserve 15% of the buyback shares for small shareholders, whichever is higher between this percentage or the number of shares entitled based on small shareholders' holdings on the record date.

Current Shareholding Pattern

As of March 31, 2026, the company's pre-buyback shareholding structure shows a diverse investor base across multiple categories:

Implementation and Management

The board has constituted a buyback committee with delegated powers to execute all necessary actions for the buyback process. Mr. Ananta Narayan Panda, Company Secretary, has been appointed as the Compliance Officer for the proposed buyback. Fintellectual Corporate Advisors Private Limited, a SEBI registered merchant banker, will serve as the Manager to the Buyback.

The board retains flexibility to increase the buyback price and decrease the number of equity shares proposed for buyback until one working day prior to the record date, provided there is no change in the aggregate buyback size. A public announcement and letter of offer detailing the complete process, timelines, and other requisite details will be released in accordance with SEBI Buyback Regulations.

Next Steps

Shareholders as of the record date of April 24, 2026 will be eligible to participate in the buyback program. The post-buyback shareholding pattern will be determined after completion of the buyback process. The buyback size excludes transaction costs such as brokerage, fees, taxes, and other incidental expenses related to the process.